39,964 Shares in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Acquired by Mirabella Financial Services LLP

Mirabella Financial Services LLP acquired a new position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVIGet Rating) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 39,964 shares of the company’s stock, valued at approximately $1,020,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Zions Bancorporation N.A. bought a new position in Maravai LifeSciences during the 1st quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. bought a new position in Maravai LifeSciences in the third quarter valued at approximately $31,000. SeaCrest Wealth Management LLC bought a new position in Maravai LifeSciences in the second quarter valued at approximately $32,000. Steward Partners Investment Advisory LLC lifted its stake in Maravai LifeSciences by 6,670.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 1,354 shares of the company’s stock valued at $38,000 after buying an additional 1,334 shares in the last quarter. Finally, PenderFund Capital Management Ltd. bought a new position in Maravai LifeSciences in the second quarter valued at approximately $44,000. Institutional investors own 48.67% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on MRVI shares. Deutsche Bank Aktiengesellschaft started coverage on shares of Maravai LifeSciences in a research note on Tuesday, December 13th. They issued a “buy” rating and a $25.00 price target on the stock. The Goldman Sachs Group cut their price target on shares of Maravai LifeSciences from $30.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, November 4th. Royal Bank of Canada started coverage on shares of Maravai LifeSciences in a research note on Tuesday, December 6th. They issued an “outperform” rating and a $22.00 price target on the stock. Credit Suisse Group cut their price target on shares of Maravai LifeSciences from $34.00 to $26.00 and set an “outperform” rating on the stock in a research note on Thursday, November 3rd. Finally, Bank of America downgraded shares of Maravai LifeSciences from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $32.00 to $17.00 in a report on Thursday, November 3rd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $23.22.

Maravai LifeSciences Price Performance

NASDAQ MRVI opened at $12.99 on Tuesday. The company has a market capitalization of $3.32 billion, a PE ratio of 7.26 and a beta of -0.25. Maravai LifeSciences Holdings, Inc. has a 12-month low of $12.16 and a 12-month high of $41.82. The firm’s 50 day moving average is $14.21 and its 200-day moving average is $20.41. The company has a quick ratio of 6.68, a current ratio of 7.22 and a debt-to-equity ratio of 0.62.

Maravai LifeSciences (NASDAQ:MRVIGet Rating) last issued its earnings results on Wednesday, November 2nd. The company reported $0.37 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.05. The business had revenue of $191.26 million for the quarter, compared to the consensus estimate of $193.83 million. Maravai LifeSciences had a net margin of 26.29% and a return on equity of 69.19%. Equities research analysts anticipate that Maravai LifeSciences Holdings, Inc. will post 1.79 earnings per share for the current fiscal year.

About Maravai LifeSciences

(Get Rating)

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

Further Reading

Institutional Ownership by Quarter for Maravai LifeSciences (NASDAQ:MRVI)

Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.